Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XOMA Corp (XOMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: XOMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.7% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 232.87M USD | Price to earnings Ratio - | 1Y Target Price 79.5 |
Price to earnings Ratio - | 1Y Target Price 79.5 | ||
Volume (30-day avg) 30192 | Beta 1 | 52 Weeks Range 18.73 - 35.00 | Updated Date 04/4/2025 |
52 Weeks Range 18.73 - 35.00 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-06 | When Before Market | Estimate -0.3033 | Actual -0.06 |
Profitability
Profit Margin -48.52% | Operating Margin (TTM) -305.86% |
Management Effectiveness
Return on Assets (TTM) -9.98% | Return on Equity (TTM) -16.2% |
Valuation
Trailing PE - | Forward PE 200 | Enterprise Value 251362383 | Price to Sales(TTM) 8.17 |
Enterprise Value 251362383 | Price to Sales(TTM) 8.17 | ||
Enterprise Value to Revenue 24.6 | Enterprise Value to EBITDA -6.91 | Shares Outstanding 11978700 | Shares Floating 8908692 |
Shares Outstanding 11978700 | Shares Floating 8908692 | ||
Percent Insiders 0.85 | Percent Institutions 60.12 |
Analyst Ratings
Rating 4 | Target Price 89 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
XOMA Corp
Company Overview
History and Background
XOMA Corp is a biotechnology company that focuses on developing antibody-based therapeutics. Founded in 1981, XOMA has undergone significant transformations, including a shift in focus towards licensing its antibody technologies after facing challenges developing its own drug candidates.
Core Business Areas
- Antibody Discovery and Licensing: XOMA focuses on licensing its antibody discovery and development technologies to other pharmaceutical and biotechnology companies. They provide a platform for generating and optimizing antibody therapeutics.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and finance. The organizational structure is designed to support its licensing-focused business model.
Top Products and Market Share
Key Offerings
- Antibody Technology Licensing: XOMA's primary offering is licensing its antibody technologies, including its XOMA YoctoMabu00ae and XOMA Human Engineeringu2122 technologies. Revenue is generated through upfront payments, milestones, and royalties. Competitors include companies offering similar antibody discovery platforms like AbCellera Biologics Inc (ABCL).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. Antibody therapeutics are a significant segment, with ongoing innovation in antibody engineering and delivery.
Positioning
XOMA is positioned as a technology provider, offering antibody discovery and development tools to other companies. Its competitive advantage lies in its established antibody technologies and expertise.
Total Addressable Market (TAM)
The TAM for antibody therapeutics is estimated to be in the hundreds of billions of dollars. XOMA's position within this TAM is as a technology enabler, capturing value through licensing agreements and royalties.
Upturn SWOT Analysis
Strengths
- Established Antibody Technologies
- Licensing-Focused Business Model
- Experienced Management Team
Weaknesses
- Dependence on Licensing Revenue
- Limited Pipeline of Proprietary Products
- Vulnerability to Changes in Partner Priorities
Opportunities
- Expansion of Licensing Agreements
- Strategic Partnerships with Larger Pharmaceutical Companies
- Development of Novel Antibody Technologies
Threats
- Competition from Other Antibody Technology Providers
- Failure of Partnered Programs
- Changes in Regulatory Landscape
Competitors and Market Share
Key Competitors
- ABCL
- LLY
- JNJ
- MRK
Competitive Landscape
XOMA's advantage lies in its specialized antibody technologies. Disadvantages include reliance on partners and limited control over drug development. Larger pharmaceutical companies have more diverse portfolios and greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by licensing agreements and milestone payments. Significant growth has been inconsistent.
Future Projections: Future growth is dependent on securing new licensing agreements and the success of partnered programs. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives involve securing new partnerships and advancing its antibody technology platform.
Summary
XOMA is a biotechnology company that licenses its antibody technologies to other firms. Its success hinges on securing licensing agreements. Its focused strategy helps it offer specialized solutions. However, its dependency on licensing revenues creates vulnerability and its market share is small compared to bigger pharmaceutical players.
Similar Companies
ABCL
Abcellera Biologics Inc
ABCL
Abcellera Biologics Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data and TAM estimations are approximate and based on available information at the time of analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XOMA Corp
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 1989-04-05 | CEO & Director Mr. Owen P. Hughes Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.xoma.com |
Full time employees 13 | Website https://www.xoma.com | ||
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.